Clinical Trials Network
We will develop a network to reduce barriers to running clinical trials in autism
Our network will connect individuals at over 120 sites across 37 countries in Europe. It is called the Clinical Trials Network.
Benefits for sites: Involvement in multi-centre studies through a single point of contact
Benefits for clinicians and researchers: Access to training and education around autism and clinical trials that will enhance services that families receive in their local centres.
Benefits for autistic people and their families. Participation in therapy studies at their local centres that are part of large-size, collaborative clinical science efforts. The network aims to demonstrate that personalised medicine approaches can improve wellbeing for autistic people who require medication.
To find out more about the network, contact Alexandra Lautarescu, King’s College London.
1. Establish a network trained to international standards to ensure the safety, integrity, and quality of autism trials conducted
2. Ensure that the network will be sustainable in the future
3. Train the next generation of leaders to design and conduct world-leading trials of treatments
Developing a clinical infrastructure
The AIMS-2-TRIALS Clinical Network builds on the infrastructure that was developed by the previous project EU-AIMS. The Network now spans 37 countries. It will conduct safe and high-quality trials of emerging therapies to support autistic people who may benefit from medical and other therapies.
To develop a high-quality Clinical Trials Network, AIMS-2-TRIALS will:
(1) Facilitate involvement in clinical trials and collaborative European-wide research projects:
- By acting as a single point of contact for potential research partners, we can facilitate and accelerate involvement in industry-led clinical trials in autism
- Initiate joint research projects – e.g. COVID-19 health and social care access for autistic people and individuals with intellectual disability: A European policy review
(2) Improve opportunities for networking and training:
- Develop a network of early-career researchers – over 120 scientists have already joined our network – and support training opportunities, internships and lab exchanges
- Organise webinars and satellite meetings at conferences to facilitate collaboration and generate networking opportunities
(3) Enhance communication and dissemination:
- Disseminate press releases of the latest developments within AIMS-2-TRIALS, new publications and project outreach activities
To join the AIMS-2-TRIALS Clinical Trials Network, or learn more about our early career researcher network, please contact Alexandra Lautarescu.